Shattuck Labs reported a third-quarter net loss of $25.2 million, or $0.14 per share, compared to a $10.1 million loss in the prior-year period. Research and development expenses rose to $21.6 million from $7.6 million as the company advanced its pipeline. The firm initiated the RECEPTIVE-CD1 Phase 2b clinical trial of SL-325 for Crohn's disease, with induction data expected in early 2028, and announced plans to start a Phase 2 trial for hidradenitis suppurativa later this year. Cash and investments increased to $196.3 million from $86.1 million, providing funding through 2029. Shattuck Labs is a clinical-stage biotechnology company pioneering the development of potentially first-in-class monoclonal and bispecific DR3 blocking antibodies for inflammatory diseases.
